A citation-based method for searching scientific literature

Sergey V Orlov, Aglaya G Iyevleva, Elena A Filippova, Alexandra M Lozhkina, Svetlana V Odintsova, Tatiana N Sokolova, Natalia V Mitiushkina, Vladislav I Tiurin, Elena V Preobrazhenskaya, Alexandr A Romanko, Alexandr S Martianov, Alexandr O Ivantsov, Svetlana N Aleksakhina, Alexandr V Togo, Evgeny N Imyanitov. Transl Oncol 2021
Times Cited: 3







List of co-cited articles
10 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
Michaël Duruisseaux, Benjamin Besse, Jacques Cadranel, Maurice Pérol, Bertrand Mennecier, Laurence Bigay-Game, Renaud Descourt, Eric Dansin, Clarisse Audigier-Valette, Lionel Moreau,[...]. Oncotarget 2017
98
66

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli,[...]. N Engl J Med 2020
247
66

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
E Felip, A T Shaw, A Bearz, D R Camidge, B J Solomon, J R Bauman, T M Bauer, S Peters, F Toffalorio, A Abbattista,[...]. Ann Oncol 2021
25
66


An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.
Viola W Zhu, Yen-Ting Lin, Dong-Wan Kim, Herbert H Loong, Misako Nagasaka, Hao To, Yvonne Li-En Ang, Chan-Young Ock, Nishan Tchekmedyian, Sai-Hong Ignatius Ou,[...]. J Thorac Oncol 2020
27
66

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis.
Maximilian J Hochmair, Hannah Fabikan, Oliver Illini, Christoph Weinlinger, Ulrike Setinek, Dagmar Krenbek, Helmut Prosch, Markus Rauter, Michael Schumacher, Ewald Wöll,[...]. Pharmaceuticals (Basel) 2020
9
66

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James,[...]. Lancet Oncol 2017
376
66

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Enriqueta Felip, Ross A Soo, D Ross Camidge, Rita Chiari, Alessandra Bearz, Chia-Chi Lin, Shirish M Gadgeel,[...]. Lancet Oncol 2018
371
66

Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients.
Christian Britschgi, Alfredo Addeo, Markus Rechsteiner, Raphaël Delaloye, Martin Früh, Giulio Metro, Marco Banini, Oliver Gautschi, Sacha I Rothschild, Peter J Wild,[...]. Front Oncol 2020
8
66

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
649
66

Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Jordi Remon, Daniele Pignataro, Silvia Novello, Francesco Passiglia. Cancer Treat Rev 2021
10
33

Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.
Anne Marie Lennon, Adam H Buchanan, Isaac Kinde, Andrew Warren, Ashley Honushefsky, Ariella T Cohain, David H Ledbetter, Fred Sanfilippo, Kathleen Sheridan, Dillenia Rosica,[...]. Science 2020
180
33


Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
Tommy Nyberg, Debra Frost, Daniel Barrowdale, D Gareth Evans, Elizabeth Bancroft, Julian Adlard, Munaza Ahmed, Julian Barwell, Angela F Brady, Carole Brewer,[...]. Eur Urol 2020
73
33

Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Lola-Jade Palmieri, Laurent Mineur, David Tougeron, Benoît Rousseau, Victoire Granger, Jean-Marc Gornet, Denis Smith, Astrid Lievre, Marie-Pierre Galais, Solene Doat,[...]. Oncologist 2020
3
33

The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.
Julien Taieb, Andreas Jung, Andrea Sartore-Bianchi, Marc Peeters, Jenny Seligmann, Aziz Zaanan, Peter Burdon, Clara Montagut, Pierre Laurent-Puig. Drugs 2019
37
33

Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.
Sergey V Silkin, Sergey S Startsev, Marina E Krasnova, Grigory A Raskin, Natalia V Mitiushkina, Aglaya G Iyevleva, Anna P Sokolenko, Evgeny N Imyanitov. J Gastrointest Cancer 2016
10
33

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Jordi Rodon, Jean-Charles Soria, Raanan Berger, Wilson H Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña,[...]. Nat Med 2019
208
33

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller,[...]. Nat Med 2019
257
33

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
150
33

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
33


Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong,[...]. N Engl J Med 2019
516
33


Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
Rafael G Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky,[...]. J Clin Oncol 2008
33

The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support.
Anja Irmisch, Ximena Bonilla, Stéphane Chevrier, Kjong-Van Lehmann, Franziska Singer, Nora C Toussaint, Cinzia Esposito, Julien Mena, Emanuela S Milani, Ruben Casanova,[...]. Cancer Cell 2021
25
33

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
Jacob J Adashek, Vivek Subbiah, Razelle Kurzrock. Trends Cancer 2021
32
33

HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
Astrid De Cuyper, Marc Van Den Eynde, Jean-Pascal Machiels. Clin Colorectal Cancer 2020
13
33

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy,[...]. Lancet Oncol 2020
465
33

Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.
Aglaya G Iyevleva, Natalia V Mitiushkina, Nina A Karaseva, Sergey V Orlov, Larisa N Volodina, Yulia E Kulikova, Alexandra M Lozhkina, Alexandr O Ivantsov, Vladislav I Tiurin, Alexandr V Togo,[...]. J Thorac Oncol 2014
11
33


EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
Jordi Remon, Lizza E L Hendriks, Andres F Cardona, Benjamin Besse. Cancer Treat Rev 2020
43
33

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Michael C Heinrich, Robin L Jones, Margaret von Mehren, Patrick Schöffski, César Serrano, Yoon-Koo Kang, Philippe A Cassier, Olivier Mir, Ferry Eskens, William D Tap,[...]. Lancet Oncol 2020
102
33

Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.
Yung Lyou, Petros Grivas, Jonathan E Rosenberg, Jean Hoffman-Censits, David I Quinn, Daniel P Petrylak, Matthew Galsky, Ulka Vaishampayan, Ugo De Giorgi, Sumati Gupta,[...]. Eur Urol 2020
9
33

Microsatellite instability in colorectal cancer-the stable evidence.
Eduardo Vilar, Stephen B Gruber. Nat Rev Clin Oncol 2010
498
33

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
Vivek Subbiah, Ulrik Lassen, Elena Élez, Antoine Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, Gerald W Prager, Richard Greil, Alexander Stein,[...]. Lancet Oncol 2020
126
33

Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing.
Esther Conde, Federico Rojo, Javier Gómez, Ana Belén Enguita, Ihab Abdulkader, Ana González, Dolores Lozano, Nuria Mancheño, Clara Salas, Marta Salido,[...]. J Clin Pathol 2022
9
33

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.
Sumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, Raanan Berger, David I Quinn, Matthew D Galsky, Juergen Wolf, Christian Dittrich, Bhumsuk Keam, Jean-Pierre Delord,[...]. Cancer Discov 2018
151
33

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
Denis L Jardim, Aaron Goodman, Debora de Melo Gagliato, Razelle Kurzrock. Cancer Cell 2021
117
33

Spectrum of APC and MUTYH germ-line mutations in Russian patients with colorectal malignancies.
G A Yanus, T A Akhapkina, A O Ivantsov, E V Preobrazhenskaya, S N Aleksakhina, I V Bizin, A P Sokolenko, N V Mitiushkina, E Sh Kuligina, E N Suspitsin,[...]. Clin Genet 2018
11
33

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Ferdinandos Skoulidis, Bob T Li, Grace K Dy, Timothy J Price, Gerald S Falchook, Jürgen Wolf, Antoine Italiano, Martin Schuler, Hossein Borghaei, Fabrice Barlesi,[...]. N Engl J Med 2021
227
33

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
256
33

Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab.
Sergey V Orlov, Magaripa A Urtenova, Maria A Sviridenko, Denis V Nesterov, Tatiana N Sokolova, Evgeny N Imyanitov. Case Rep Oncol 2020
5
33

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Jean-Yves Douillard, Kelly S Oliner, Salvatore Siena, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, Gyorgy Bodoky, David Cunningham, Jacek Jassem,[...]. N Engl J Med 2013
33


Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
Miguel Garcia-Pardo, Laura Ortega, María Jesús Fernández-Aceñero, Pilar García Alfonso, Miguel Martín, Andrés J Muñoz. J Gastrointest Cancer 2021
2
50

A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial).
Kenta Takahashi, Eri Ishibashi, Toshio Kubo, Yohei Harada, Hideyuki Hayashi, Masayuki Kano, Yasushi Shimizu, Hidekazu Shirota, Yukiko Mori, Manabu Muto,[...]. Medicine (Baltimore) 2020
5
33

Emerging strategies to target RAS signaling in human cancer therapy.
Kun Chen, Yalei Zhang, Ling Qian, Peng Wang. J Hematol Oncol 2021
19
33

Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine.
Sebastian Mondaca, Pedram Razavi, Chongrui Xu, Michael Offin, Mackenzie Myers, Maurizio Scaltriti, Jaclyn F Hechtman, Mikaela Bradley, Eileen M O'Reilly, Michael F Berger,[...]. JCO Precis Oncol 2019
13
33

Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).
Su Jin Lee, Tae Min Kim, Yu Jung Kim, Kee-Taek Jang, Hyo Jin Lee, Soon Nam Lee, Mi Sun Ahn, In Gyu Hwang, Suee Lee, Moon-Hee Lee,[...]. Oncologist 2015
39
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.